search
Back to results

Gabapentin Reduces Opioid Use Postoperatively ("GROUP Study") (GROUP)

Primary Purpose

Pelvic Organ Prolapse

Status
Unknown status
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Gabapentin
placebo
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pelvic Organ Prolapse

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • women age 18 years and older
  • uterovaginal prolapse with or without stress urinary incontinence
  • booked for vaginal hysterectomy, anterior and/or posterior vaginal repair, with or without TVT

Exclusion Criteria:

  • Women already on gabapentin for other indications
  • Women with proven allergy or sensitivity to gabapentin
  • Women with a contraindication to gabapentin
  • Women unable to understand spoken English

Sites / Locations

  • Department of Obstetrics and Gynecology, Mount Sinai HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

gabapentin

placebo

Arm Description

gabapentin 300-600 mg 1 hour preop

placebo capsule(s) 1 hour preop

Outcomes

Primary Outcome Measures

opioid consumption postop
total opioid use 24 hours after surgery

Secondary Outcome Measures

Full Information

First Posted
December 17, 2016
Last Updated
February 12, 2017
Sponsor
Mount Sinai Hospital, Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT02999724
Brief Title
Gabapentin Reduces Opioid Use Postoperatively ("GROUP Study")
Acronym
GROUP
Official Title
Gabapentin Reduces Opioid Use Postoperatively ("GROUP Study"): A Randomized Control Trial in Women Undergoing Reconstructive Pelvic Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 2017 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
January 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mount Sinai Hospital, Canada

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Gabapentin is a medication used primarily to treat seizures and pain. Studies have shown that this medication can help reduce pain after surgery, including hysterectomy, where the uterus or "womb" is removed. Opioids are the first choice for pain medication administered after surgery, but carry significant side effects. Several studies have demonstrated that if patients are given gabapentin before surgery, they require less opioids after surgery. However, there have not been any studies examining gabapentin's effects on post-operative pain in urogynecologic surgery, which treats pelvic organ prolapse and urinary incontinence. Pelvic organ prolapse occurs when female pelvic floor supports have weakened and therefore patients experience a "bulge" or "pressure" in the vagina. Patients with these conditions are typically offered medical treatments, but some may require surgery, and this usually consists of vaginal hysterectomy, pelvic floor repair, and a mid-urethral sling to treat any concurrent urinary incontinence. Our study aims to look at the effect of gabapentin given to patients undergoing urogynecologic surgery on their pain levels after surgery, including the amount of opioid pain medication required. We hypothesize that the patients who receive gabapentin before surgery will require significantly less opioids. Over a six-month period, patients seen in Urogynecology clinics will be invited to participate in the study. Women who are already on gabapentin for other reasons, have an allergy to gabapentin, have a reason they cannot take gabapentin, or who cannot understand spoken English will be excluded from the study. After providing informed consent, they will be randomized to either receive gabapentin or a placebo pill. They will receive the standard surgical care, including the usual anesthesia for surgery and routine pain medications available after surgery. We will then compare the differences in opioid consumption in the first 24 hours after surgery as well as the time from the end of surgery to leaving to the recovery room and the length of recovery room stay between the gabapentin and placebo groups. We will also analyze the differences in anxiety, drowsiness, pain, and nausea as rated by the patients in each group.
Detailed Description
This study will be a randomized double blinded placebo controlled trial. All women presenting to Mount Sinai Hospital eligible for surgery with pelvic organ prolapse symptoms requiring hysterectomy with other pelvic reconstruction (repair of cystocele and/or rectocele, with or without TVT) will be provided with a written informed consent to be randomized to either receiving pre-operative gabapentin single dose or placebo 2 hours prior to surgery. The single dose of gabapentin will be 600 mg for patients under 65 years old and 300 mg for those 65 years old and above. All patients will have pre-operative assessment according to the usual routine that will include urogynecological history taking, physical examination, urodynamic testing and blood work. Urodynamic testing will include measurement of the post-void residual by urethral catheterization or bladder scan, uroflowmetry, a filling cystometrogram and urethral pressure profilometry. Medication and placebo will be prepared by the hospital pharmacy to look alike to blind staff and patients. Medication or placebo will be given with other pre-anesthesia medications such as celecoxib and acetaminophen according to usual protocol. Routine peri-operative surgical/anesthesia management will be unchanged from the usual care. Post-operative pain score will be measured using a visual analogue scale (VAS) from 1 to 10. Total Opioids use during the first 24 hours after surgery will be calculated from patients' paper and electronic chart, and conversion will be made to morphine equivalents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Organ Prolapse

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
gabapentin
Arm Type
Experimental
Arm Description
gabapentin 300-600 mg 1 hour preop
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo capsule(s) 1 hour preop
Intervention Type
Drug
Intervention Name(s)
Gabapentin
Intervention Description
Gabapentin 300-600 mg 1 hour preop
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
placebo capsule
Intervention Description
placebo capsule(s) 1 hour preop
Primary Outcome Measure Information:
Title
opioid consumption postop
Description
total opioid use 24 hours after surgery
Time Frame
24 hours

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: women age 18 years and older uterovaginal prolapse with or without stress urinary incontinence booked for vaginal hysterectomy, anterior and/or posterior vaginal repair, with or without TVT Exclusion Criteria: Women already on gabapentin for other indications Women with proven allergy or sensitivity to gabapentin Women with a contraindication to gabapentin Women unable to understand spoken English
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Danny Lovatsis, MD
Phone
416-586-4566
Email
danny.lovatsis@sinaihealthsystem.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Adrienne Li, MD
Phone
416-586-4566
Email
adrienne.lk.li@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Danny Lovatsis, MD
Organizational Affiliation
Sinai Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Obstetrics and Gynecology, Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G1Z5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Danny Lovatsis, MD MSc
Phone
4165864566
Email
dlovatsis@mtsinai.on.ca
First Name & Middle Initial & Last Name & Degree
Adrienne Li, MD
Phone
416-586-4566
Email
adrienne.lk.li@gmail.com
First Name & Middle Initial & Last Name & Degree
Danny Lovatsis, MD MSc
First Name & Middle Initial & Last Name & Degree
Adrienne Li, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29564507
Citation
Li ALK, Wadsworth K, Siddiqui NT, Alarab M, McDermott CD, Lemos N, Dawood A, Lovatsis D. Does low-dose gapapentin reduce opioid use postoperatively?: A randomized controlled trial in women undergoing reconstructive pelvic surgery. Int Urogynecol J. 2019 Feb;30(2):211-217. doi: 10.1007/s00192-018-3617-3. Epub 2018 Mar 21.
Results Reference
derived

Learn more about this trial

Gabapentin Reduces Opioid Use Postoperatively ("GROUP Study")

We'll reach out to this number within 24 hrs